These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29731229)

  • 1. Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect.
    Hescot S; Haissaguerre M; Pautier P; Kuhn E; Schlumberger M; Berdelou A
    Eur J Cancer; 2018 Jul; 97():57-58. PubMed ID: 29731229
    [No Abstract]   [Full Text] [Related]  

  • 2. Rare case of delayed onset colitis due to immunotherapy for malignant melanoma.
    Sarofim M; Winn R
    ANZ J Surg; 2019 Oct; 89(10):E472-E473. PubMed ID: 30136350
    [No Abstract]   [Full Text] [Related]  

  • 3. Sarcoidosis-Like Granulomatous Reaction Associated With Pembrolizumab Immunotherapy.
    Gayá García-Manso I; García Ródenas MDM; Barroso Medel ME; Illán Gambín FJ
    Arch Bronconeumol (Engl Ed); 2018 Nov; 54(11):592-593. PubMed ID: 29801680
    [No Abstract]   [Full Text] [Related]  

  • 4. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
    Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
    Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
    [No Abstract]   [Full Text] [Related]  

  • 5. Tisotumab vedotin (Tivdak) for cervical cancer.
    Med Lett Drugs Ther; 2024 Jun; 66(1705):e109-e110. PubMed ID: 38905529
    [No Abstract]   [Full Text] [Related]  

  • 6. A patient with pembrolizumab-induced fatal polymyositis.
    Tay SH; Wong AS; Jeyasekharan AD
    Eur J Cancer; 2018 Mar; 91():180-182. PubMed ID: 29329695
    [No Abstract]   [Full Text] [Related]  

  • 7. Gas Bubbles: A Persistent Problem with Immunotherapy.
    Yik B; Shah N
    Dig Dis Sci; 2021 Aug; 66(8):2542-2544. PubMed ID: 33403485
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab-associated inflammatory myopathy.
    Gandiga PC; Wang AR; Gonzalez-Rivera T; Sreih AG
    Rheumatology (Oxford); 2018 Feb; 57(2):397-398. PubMed ID: 29088490
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.
    Nasr F; El Rassy E; Maalouf G; Azar C; Haddad F; Helou J; Robert C
    Eur J Cancer; 2018 Mar; 91():171-173. PubMed ID: 29287903
    [No Abstract]   [Full Text] [Related]  

  • 10. Pembrolizumab tunes up chemotherapy in cervical cancer.
    Romero D
    Nat Rev Clin Oncol; 2021 Dec; 18(12):747. PubMed ID: 34616034
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of immunotherapy colitis: Special considerations in the COVID-19 era.
    Grover S; Bond SA; Mansour MK; Friedman S
    Cancer; 2020 Nov; 126(21):4630-4633. PubMed ID: 32797685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confounding Case of Hemolysis in a Patient with Acute Leukemia.
    Tesfazghi MT; Farnsworth CW; Roper SM; Gronowski AM; Dietzen DJ
    Clin Chem; 2018 Dec; 64(12):1690-1694. PubMed ID: 30487187
    [No Abstract]   [Full Text] [Related]  

  • 13. Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings.
    Imai R; Ono M; Nishimura N; Suzuki K; Komiyama N; Tamura T
    J Thorac Oncol; 2019 Feb; 14(2):e36-e38. PubMed ID: 30391574
    [No Abstract]   [Full Text] [Related]  

  • 14. Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum.
    Burillo-Martinez S; Morales-Raya C; Prieto-Barrios M; Rodriguez-Peralto JL; Ortiz-Romero PL
    JAMA Dermatol; 2017 Jul; 153(7):721-722. PubMed ID: 28467548
    [No Abstract]   [Full Text] [Related]  

  • 15. Predisposition to multi-drug hypersensitivity after administration of mogamulizumab.
    Miyagawa F; Yamamoto S; Miyao M; Nishikawa M; Ogawa K; Asada H
    Eur J Dermatol; 2018 Aug; 28(4):526-528. PubMed ID: 29952299
    [No Abstract]   [Full Text] [Related]  

  • 16. Experts To Address Rare, Toxic Downside of Immunotherapy.
    Jenks S
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 30053210
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-PD1/PDL1 induced psoriasis.
    Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
    Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia.
    Hellman JB; Traynis I; Lin LK
    Orbit; 2019 Jun; 38(3):244-247. PubMed ID: 29985683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cascade of Pembrolizumab-Induced Autoimmune Toxicities with Mixed Responses to Corticosteroids.
    Habib R; Gordon J; Zielinski R
    J Thorac Oncol; 2018 Jan; 13(1):e8-e9. PubMed ID: 29258672
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
    Pradère P; Boutros C; Scoazec JY; Dorfmüller P; Leroy-Ladurie F; Boulate D; Le Pavec J; Robert C
    Eur J Cancer; 2018 Apr; 93():144-146. PubMed ID: 29402507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.